{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:05:48Z","timestamp":1790114748461,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T00:00:00Z","timestamp":1112572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,4,4]],"date-time":"2005-04-04T00:00:00Z","timestamp":1112572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Various dermatological conditions have been reported during tumor necrosis factor (TNF)-\u03b1-blocking therapy, but until now no prospective studies have been focused on this aspect. The present study was set up to investigate the number and nature of clinically important dermatological conditions during TNF-\u03b1-blocking therapy in patients with rheumatoid arthritis (RA). RA patients starting on TNF-\u03b1-blocking therapy were prospectively followed up. The numbers and natures of dermatological events giving rise to a dermatological consultation were recorded. The patients with a dermatological event were compared with a group of prospectively followed up RA control patients, naive to TNF-\u03b1-blocking therapy and matched for follow-up period. 289 RA patients started TNF-\u03b1-blocking therapy. 128 dermatological events were recorded in 72 patients (25%) during 911 patient-years of follow-up. TNF-\u03b1-blocking therapy was stopped in 19 (26%) of these 72 patients because of the dermatological event. More of the RA patients given TNF-\u03b1-blocking therapy (25%) than of the anti-TNF-\u03b1-naive patients (13%) visited a dermatologist during follow-up (<jats:italic>P<\/jats:italic> &lt; 0.0005). Events were recorded more often during active treatment (0.16 events per patient-year) than during the period of withdrawal of TNF-\u03b1-blocking therapy (0.09 events per patient-year, <jats:italic>P<\/jats:italic> &lt; 0.0005). The events recorded most frequently were skin infections (<jats:italic>n<\/jats:italic> = 33), eczema (<jats:italic>n<\/jats:italic> = 20), and drug-related eruptions (<jats:italic>n<\/jats:italic> = 15). Other events with a possible relation to TNF-\u03b1-blocking therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid-papulosis-like eruption. This study is the first large prospective study focusing on dermatological conditions during TNF-\u03b1-blocking therapy. It shows that dermatological conditions are a significant and clinically important problem in RA patients receiving TNF-\u03b1-blocking therapy.<\/jats:p>","DOI":"10.1186\/ar1724","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T06:13:42Z","timestamp":1112681622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":216,"title":["Dermatological conditions during TNF-\u03b1-blocking therapy in patients with rheumatoid arthritis: a prospective study"],"prefix":"10.1186","volume":"7","author":[{"given":"Marcel","family":"Flendrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynand HPM","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjonne CW","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke MGJ","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter CM","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet LCM","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,4,4]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, et al: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999, 130: 478-486.","journal-title":"Ann Intern Med"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002\/art.10697.","journal-title":"Arthritis Rheum"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/art.10710","volume":"48","author":"DJ Lovell","year":"2003","unstructured":"Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003, 48: 218-226. 10.1002\/art.10710.","journal-title":"Arthritis Rheum"},{"key":"1603_CR5","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003, 48: 1667-1675. 10.1002\/art.11017.","journal-title":"Arthritis Rheum"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002, 359: 1187-1193. 10.1016\/S0140-6736(02)08215-6.","journal-title":"Lancet"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016\/S0140-6736(00)02530-7.","journal-title":"Lancet"},{"key":"1603_CR8","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 354: 1932-1939. 10.1016\/S0140-6736(99)05246-0.","journal-title":"Lancet"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004, 50: 1400-1411. 10.1002\/art.20217.","journal-title":"Arthritis Rheum"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","volume":"40","author":"GS Bleumink","year":"2001","unstructured":"Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC: Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology. 2001, 40: 1317-1319. 10.1093\/rheumatology\/40.11.1317.","journal-title":"Rheumatology"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.7326\/0003-4819-131-8-199910190-00031","volume":"131","author":"PH Brion","year":"1999","unstructured":"Brion PH, Mittal HA, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis [letter]. Ann Intern Med. 1999, 131: 634-","journal-title":"Ann Intern Med"},{"key":"1603_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.10348","volume":"46","author":"PD Kent","year":"2002","unstructured":"Kent PD, Davis JM, Davis MDP, Matteson EL: Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum. 2002, 46: 2257-2258. 10.1002\/art.10348.","journal-title":"Arthritis Rheum"},{"key":"1603_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1046\/j.1365-2133.2002.4653_4.x","volume":"146","author":"L Misery","year":"2002","unstructured":"Misery L, Perrot JL, Gentil PA, Pallot PB, Cambazard F, Alexandre C: Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002, 146: 334-335. 10.1046\/j.1365-2133.2002.4653_4.x.","journal-title":"Br J Dermatol"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/archderm.138.9.1258","volume":"138","author":"G Vergara","year":"2002","unstructured":"Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC: Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol. 2002, 138: 1258-1259. 10.1001\/archderm.138.9.1258.","journal-title":"Arch Dermatol"},{"key":"1603_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0190-9622(03)70103-0","volume":"49","author":"RC Wright","year":"2003","unstructured":"Wright RC: Atopic dermatitis-like eruption precipitated by infliximab. JAm Acad Dermatol. 2003, 49: 160-161.","journal-title":"JAm Acad Dermatol"},{"key":"1603_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"1603_CR17","first-page":"ii30","volume":"62","author":"M Flendrie","year":"2003","unstructured":"Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003, 62 (Suppl 2): ii30-ii33.","journal-title":"Ann Rheum Dis"},{"key":"1603_CR18","first-page":"680","volume":"30","author":"R Rau","year":"2003","unstructured":"Rau R, Sander O, van Riel PL, van de Putte LB, Hasler F, Zaug M, Kneer J, van der AP, Stevens RM: Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol. 2003, 30: 680-690.","journal-title":"J Rheumatol"},{"key":"1603_CR19","first-page":"14","volume":"31","author":"PMJ Welsing","year":"2004","unstructured":"Welsing PMJ, van Riel PLCM: The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol. 2004, 31: 14-21.","journal-title":"J Rheumatol"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48.","journal-title":"Arthritis Rheum"},{"key":"1603_CR21","first-page":"1634","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"R Stern","year":"1999","unstructured":"Stern R, Wintroub BU: Cutaneous reactions to drugs. Fitzpatrick's Dermatology in General Medicine. Edited by: Freedberg IM, Eisen A, Wolff K, Austen KF, Goldsmith LA, Katz SI. 1999, New York: McGraw-Hill, 1634-1642. 5","edition":"5"},{"key":"1603_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0190-9622(83)70049-6","volume":"8","author":"JL Jorizzo","year":"1983","unstructured":"Jorizzo JL, Daniels JC: Dermatologic conditions reported in patients with rheumatoid arthritis. J Am Acad Dermatol. 1983, 8: 439-457.","journal-title":"J Am Acad Dermatol"},{"key":"1603_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-4362.1982.tb02037.x","volume":"21","author":"WL Sibbitt","year":"1982","unstructured":"Sibbitt WL, Williams RC: Cutaneous manifestations of rheumatoid arthritis. Int J Dermatol. 1982, 21: 563-572.","journal-title":"Int J Dermatol"},{"key":"1603_CR24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1346-8138.1995.tb03396.x","volume":"22","author":"T Yamamoto","year":"1995","unstructured":"Yamamoto T, Ohkubo H, Nishioka K: Skin manifestations associated with rheumatoid arthritis. J Dermatol. 1995, 22: 324-329.","journal-title":"J Dermatol"},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00296-003-0294-3","volume":"23","author":"A Bicer","year":"2003","unstructured":"Bicer A, Tursen U, Cimen OB, Kaya TI, Ozisik S, Ikizoglu G, Erdogan C: Prevalence of dermatophytosis in patients with rheumatoid arthritis. Rheumatol Int. 2003, 23: 37-40.","journal-title":"Rheumatol Int"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002, 46: 2287-2293. 10.1002\/art.10524.","journal-title":"Arthritis Rheum"},{"key":"1603_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/rheumatology\/32.9.798","volume":"32","author":"SM Wilkinson","year":"1993","unstructured":"Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT: Suspected cutaneous drug toxicity in rheumatoid arthritis \u2013 an evaluation. Br J Rheumatol. 1993, 32: 798-803.","journal-title":"Br J Rheumatol"},{"key":"1603_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/ard.53.4.224","volume":"53","author":"MJ van der Veen","year":"1994","unstructured":"van der Veen MJ, van der HA, Kruize AA, Bijlsma JW: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994, 53: 224-228.","journal-title":"Ann Rheum Dis"},{"key":"1603_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","volume":"43","author":"FW Miller","year":"2000","unstructured":"Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA: Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 2000, 43: 243-249. 10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K.","journal-title":"Arthritis Rheum"},{"key":"1603_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0889-857X(02)00101-1","volume":"29","author":"B Bresnihan","year":"2003","unstructured":"Bresnihan B, Cunnane G: Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003, 29: 185-202. 10.1016\/S0889-857X(02)00101-1.","journal-title":"Rheum Dis Clin North Am"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001, 345: 1098-1104. 10.1056\/NEJMoa011110.","journal-title":"N Engl J Med"},{"key":"1603_CR32","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons DP: Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis. 2004, 63: 1538-1543. 10.1136\/ard.2004.024737.","journal-title":"Ann Rheum Dis"},{"key":"1603_CR33","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/art.11301","volume":"48","author":"T Ellerin","year":"2003","unstructured":"Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003, 48: 3013-3022. 10.1002\/art.11301.","journal-title":"Arthritis Rheum"},{"key":"1603_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/art.11151","volume":"48","author":"MG Netea","year":"2003","unstructured":"Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum. 2003, 48: 1853-1857. 10.1002\/art.11151.","journal-title":"Arthritis Rheum"},{"key":"1603_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/pmj.78.915.47","volume":"78","author":"AT Chan","year":"2002","unstructured":"Chan AT, Cleeve V, Daymond TJ: Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002, 78: 47-48. 10.1136\/pmj.78.915.47.","journal-title":"Postgrad Med J"},{"key":"1603_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S0025-6196(11)62418-X","volume":"76","author":"M Baghai","year":"2001","unstructured":"Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001, 76: 653-656.","journal-title":"Mayo Clin Proc"},{"key":"1603_CR37","first-page":"1900","volume":"25","author":"B Hernandez-Cruz","year":"1998","unstructured":"Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J: Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol. 1998, 25: 1900-1907.","journal-title":"J Rheumatol"},{"key":"1603_CR38","first-page":"1912","volume":"31","author":"MJ Wasserman","year":"2004","unstructured":"Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC: Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004, 31: 1912-1917.","journal-title":"J Rheumatol"},{"key":"1603_CR39","first-page":"481","volume":"21","author":"AD Hartung","year":"2003","unstructured":"Hartung AD, Bohnert A, Hackstein H, Ohly A, Schmidt KL, Bein G: Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis. Clin Exp Rheumatol. 2003, 21: 481-484.","journal-title":"Clin Exp Rheumatol"},{"key":"1603_CR40","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/rheumatology\/39.9.1020","volume":"39","author":"P Hilliquin","year":"2000","unstructured":"Hilliquin P, Allanore Y, Coste J, Renoux M, Kahan A, Menkes CJ: Reduced incidence and prevalence of atopy in rheumatoid arthritis. Results of a case-control study. Rheumatology. 2000, 39: 1020-1026. 10.1093\/rheumatology\/39.9.1020.","journal-title":"Rheumatology"},{"key":"1603_CR41","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.61.11.968","volume":"61","author":"M Rudwaleit","year":"2002","unstructured":"Rudwaleit M, Andermann B, Alten R, Sorensen H, Listing J, Zink A, Sieper J, Braun J: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis. 2002, 61: 968-974. 10.1136\/ard.61.11.968.","journal-title":"Ann Rheum Dis"},{"key":"1603_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1034\/j.1600-0463.2003.1111004.x","volume":"111","author":"AR Olsson","year":"2003","unstructured":"Olsson AR, Wingren G, Skogh T, Svernell O, Ernerudh J: Allergic manifestations in patients with rheumatoid arthritis. APMIS. 2003, 111: 940-944. 10.1034\/j.1600-0463.2003.1111004.x.","journal-title":"APMIS"},{"key":"1603_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1067\/mjd.2002.120568","volume":"46","author":"JG Krueger","year":"2002","unstructured":"Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002, 46: 1-23. 10.1067\/mjd.2002.120568.","journal-title":"J Am Acad Dermatol"},{"key":"1603_CR44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/art.11033","volume":"48","author":"E Carlson","year":"2003","unstructured":"Carlson E, Rothfield N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1165-1166. 10.1002\/art.11033.","journal-title":"Arthritis Rheum"},{"key":"1603_CR45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1191\/0961203302lu236cr","volume":"11","author":"E Favalli","year":"2002","unstructured":"Favalli E, Sinigaglia L, Varenna M, Arnoldi C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002, 11: 753-755. 10.1191\/0961203302lu236cr.","journal-title":"Lupus"},{"key":"1603_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"N Shakoor","year":"2002","unstructured":"Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002, 359: 579-580. 10.1016\/S0140-6736(02)07714-0.","journal-title":"Lancet"},{"key":"1603_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/ard.61.9.793","volume":"61","author":"P Geborek","year":"2002","unstructured":"Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002, 61: 793-798. 10.1136\/ard.61.9.793.","journal-title":"Ann Rheum Dis"},{"key":"1603_CR48","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol. 2003, 30: 2287-2291.","journal-title":"J Rheumatol"},{"key":"1603_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/rheumatology\/41.1.116","volume":"41","author":"ME McCain","year":"2002","unstructured":"McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology. 2002, 41: 116-117. 10.1093\/rheumatology\/41.1.116.","journal-title":"Rheumatology"},{"key":"1603_CR50","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001, 357: 1842-1847. 10.1016\/S0140-6736(00)04954-0.","journal-title":"Lancet"},{"key":"1603_CR51","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, et al: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003, 139: 1627-1632. 10.1001\/archderm.139.12.1627.","journal-title":"Arch Dermatol"},{"key":"1603_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1345\/aph.1C477","volume":"38","author":"MM Verea","year":"2004","unstructured":"Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E: Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004, 38: 54-57. 10.1345\/aph.1C477.","journal-title":"Ann Pharmacother"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar1724\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1724.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:22:02Z","timestamp":1728382922000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar1724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,4]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,3]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/ar1724","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,4]]},"assertion":[{"value":"3 January 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R666"}}